Psilocybin in Oceania: Australia, New Zealand & Pacific

Australia: TGA Approval 2023

Australia made history on February 1, 2023, when the Therapeutic Goods Administration (TGA) issued its final decision to reclassify psilocybin and MDMA from Schedule 9 (Prohibited Substance) to Schedule 8 (Controlled Drug) for specific therapeutic indications. The decision took effect on July 1, 2023, making Australia the first country in the world to formally recognize these substances as therapeutic medicines at the national level.

What Was Approved

• Psilocybin: Approved for use in treatment-resistant depression (TRD) — defined as depression that has not responded to at least two adequate antidepressant trials.
• MDMA: Approved simultaneously for post-traumatic stress disorder (PTSD).
• Remaining Schedule 9: Both substances remain Schedule 9 (fully prohibited) for any indication not covered by the TGA approval, including recreational use. Unauthorized possession remains a state/territory offense.
• Evidence base: The TGA decision was driven by evidence from global clinical trials including MAPS Phase 3 MDMA trials and COMPASS Pathways / Imperial College London psilocybin studies.

How Patients Access Psilocybin Therapy

Access is strictly controlled through the Authorised Prescriber (AP) pathway:

• Psychiatrists apply for Authorised Prescriber status through their state or territory health department, or directly through the TGA.
• The psychiatrist must have specific training in psychedelic-assisted psychotherapy.
• Treatment occurs in a clinical setting with continuous monitoring.
• A typical course involves 1–3 dosing sessions supported by psychological preparation and integration sessions before and after each dose.
• General practitioners cannot prescribe psilocybin — specialist psychiatrist referral is required.
• Mind Medicine Australia (mindmedicineaustralia.org) maintains an updated list of psychiatrists with Authorised Prescriber status.

Cost and Access Realities

Access to psilocybin therapy in Australia is currently limited by cost and geographic availability:

• The treatment course is not covered by Medicare or the Pharmaceutical Benefits Scheme (PBS) as of 2024.
• Estimated total cost: AUD $25,000–$35,000 for a complete treatment course including psychiatric consultations, preparation sessions, dosing sessions, and integration.
• Several clinical trials offer subsidized or free access — MAPS Australia, PRISM, and the Psychae Institute conduct active trials.
• Primarily available in major cities: Sydney, Melbourne, Brisbane, and Perth have the most active prescribers. Regional access is very limited.
• Private health insurance rarely covers the treatment as of 2024, though this may change.

Key Organizations

• Mind Medicine Australia: Leading advocacy organization; maintains prescriber directory and patient support resources.
• PRISM (Psychedelic Research in Science and Medicine): Leading Australian research body conducting clinical trials.
• Psychae Institute (Melbourne): Integrates clinical research and therapeutic service delivery.
• Monash University and University of Melbourne: Active trial sites.
• St Vincent's Hospital Sydney: MDMA-assisted therapy trials.

New Zealand: Class A Prohibition

New Zealand maintains strict prohibition of psilocybin under the Misuse of Drugs Act 1975. Psilocybin is classified as a Class A controlled drug — the highest restriction level — carrying penalties of up to 8 years imprisonment for possession and up to life imprisonment for supply or manufacture.

As of 2024, Medsafe (New Zealand's medicine regulator, equivalent to the TGA) has not approved psilocybin for any therapeutic indication. There is no compassionate use or clinical trial exemption pathway comparable to Australia's Authorised Prescriber model.

Growing academic interest exists at the University of Auckland and University of Otago, and New Zealand researchers participate in international psychedelic research networks. However, domestic clinical trials in New Zealand have not advanced to the stage seen in Australia. Drug policy reform advocates in New Zealand are watching the Australian model closely.

Pacific Islands

Pacific Island nations generally adopted controlled substance legislation modeled on British or American frameworks, treating psilocybin as a prohibited substance. Enforcement varies significantly by island nation and geographic remoteness.

Vanuatu

Vanuatu has no specific psilocybin legislation listed in easily accessible national drug schedules. The nation has a growing kava tourism industry and is culturally open to traditional plant medicine practices. However, this does not constitute a legal framework for psilocybin, and travelers should not assume permissiveness extends to imported substances.

Fiji, Samoa, Tonga

These nations have adopted controlled substance legislation that would prohibit psilocybin under general psychotropic substance provisions. Enforcement in remote communities with traditional plant medicine practices may be limited, but formal legal protection does not exist. International travelers bringing substances to these islands face serious legal risk.

The Australian Model: Global Significance

Australia's TGA decision is significant beyond its domestic impact. It represents the first national regulatory approval of psilocybin as a medicine and has accelerated policy discussions in other countries:

• Canada: Health Canada is watching the Australian model as it evaluates expansion of its Special Access Program for psilocybin.
• United Kingdom: The UK's MHRA and ACMD are conducting reviews informed in part by Australia's approach.
• European Union: The EMA (European Medicines Agency) has not yet acted on psilocybin but Australia's regulatory framework provides a reference model.
• New Zealand: Medsafe is actively monitoring international developments and the Therapeutics Products Bill may eventually create mechanisms similar to Australia's AP pathway.

Frequently Asked Questions

Is psilocybin legal in Australia?

Psilocybin is legal in Australia only for therapeutic use under the TGA's Authorised Prescriber pathway, which took effect July 1, 2023. Authorized psychiatrists can prescribe psilocybin for treatment-resistant depression. Recreational possession, cultivation, and supply remain illegal under state and territory drug laws, with criminal penalties.

Can I access psilocybin therapy in Australia as a tourist?

The TGA's Authorised Prescriber pathway does not explicitly require Australian citizenship or permanent residency. However, the practical barriers are significant: you would need a diagnosis of treatment-resistant depression from an Australian psychiatrist, a referral to an Authorised Prescriber, and sufficient time for the treatment course. The cost (AUD $25,000–$35,000) and the need for established clinical relationships make access-as-a-tourist very difficult in practice.

How does Australia's psilocybin approval compare to Oregon's?

Both systems restrict psilocybin to clinical/facilitated contexts, but they differ structurally. Australia's TGA model requires a physician (psychiatrist) prescriber and a medical indication (treatment-resistant depression). Oregon's model operates through licensed Psilocybin Service Centers with licensed facilitators (not necessarily physicians) and does not require a clinical diagnosis — it is more of a wellness model than a medical one.

Is psilocybin legal in New Zealand?

No. Psilocybin is a Class A controlled drug in New Zealand under the Misuse of Drugs Act 1975. There is no therapeutic approval pathway equivalent to Australia's, and possession carries up to 8 years imprisonment. New Zealand has not yet advanced domestic clinical trial programs for psilocybin.

How much does psilocybin therapy cost in Australia?

An estimated AUD $25,000–$35,000 for a full treatment course as of 2024. This includes multiple psychiatric consultations, preparation sessions, 1–3 dosing sessions (each typically 6–8 hours), and integration sessions. Medicare does not currently cover the treatment. Some clinical trials offer subsidized or no-cost access; visit the PRISM and Mind Medicine Australia websites for current trial listings.

What is the difference between Schedule 8 and Schedule 9 in Australia?

Schedule 9 (Prohibited Substance) is for substances with no recognized therapeutic use — psilocybin's previous classification. Schedule 8 (Controlled Drug) recognizes that a substance has therapeutic value but requires strict controls, including prescription requirements, dispensing records, and secure storage. The reclassification from Schedule 9 to Schedule 8 created the legal mechanism for therapeutic prescribing.

What is Mind Medicine Australia?

Mind Medicine Australia is a non-profit organization that advocates for the therapeutic use of psychedelic medicines and provides education and support. They played a significant advocacy role in the TGA decision and maintain a directory of Authorised Prescribers, patient support resources, and information on clinical trials. Their website is mindmedicineaustralia.org.

Are there clinical trials for psilocybin in Australia?

Yes. Active clinical trials as of 2024 include those conducted by PRISM (Psychedelic Research in Science and Medicine), the Psychae Institute in Melbourne, Monash University, and others. Clinical trial participation may offer subsidized or no-cost access to psilocybin therapy for qualifying individuals. Search the Australian New Zealand Clinical Trials Registry (ANZCTR) for current listings.

Can I bring psilocybin mushrooms from the Netherlands to Australia?

No. Transporting any psilocybin-containing substance into Australia — regardless of its legal status at the point of origin — constitutes drug importation and is a serious federal crime under the Criminal Code Act 1995. The TGA approval does not create any pathway for individuals to import psilocybin. Even within Australia, individual patients do not hold the substance — it is administered in a clinical setting.

Is psilocybin decriminalized in any Pacific Island nations?

No Pacific Island nation has formally decriminalized psilocybin. Some remote communities and smaller island nations have limited drug enforcement infrastructure, and traditional plant medicine practices receive informal tolerance. However, this represents enforcement pragmatics rather than legal decriminalization, and international travelers should not assume safety.